Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria

References

• Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981): 1975–1982.
   Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   Google Scholar
• Vanholder R, Davenport A, Hannedouche T, et al. Reimbursement of dialysis: a comparison of seven countries. J Am Soc Nephrol. 2012;23(8):1291.
   Google Scholar
• Vanholder R, Annemans L, Brown E, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393–409.
   Google Scholar
• Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034–2047.
   Google Scholar
• Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the us food and drug administration and European Medicines Agency. Am J Kidney Diseases. 2020;75(1):84–104.
   Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   Google Scholar
• Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232.
   Google Scholar
• Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273–3277.
   Google Scholar
• Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–563.
   Google Scholar
• Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007 Mar;27(2):195–207.
   Google Scholar
• Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994 Feb;45(2):612–622.
   Google Scholar
• Qian Y, Feldman E, Pennathur S, et al. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes. 2008;57(6):1439–1445.
   Google Scholar
• Wada T, Shimizu M, Yokoyama H, et al. Nodular lesions and mesangiolysis in diabetic nephropathy. Clin Exp Nephrol. 2013;17(1):3–9.
   Google Scholar
• Berger M, Monks D, Wanner C, et al. Diabetic nephropathy: an inherited disease or just a diabetic complication? Kidney Blood Press Res. 2003;26(3):143–154.
   Google Scholar
• Diabetes C, Complications Trial Research G, Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
   Google Scholar
• Thomas MC. Targeting the pathobiology of diabetic kidney disease. Adv Chronic Kidney Dis. 2021 Jul;28(4):282–289.
   Google Scholar
• Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787–790.
   Google Scholar
• Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996 Mar;19(3):257–267.
   Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820.
   Google Scholar
• Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A. 2000;97(22):12222–12226.
   Google Scholar
• Vander Jagt DL, Robinson B, Taylor KK, et al. Aldose reductase from human skeletal and heart muscle. Interconvertible forms related by thiol-disulfide exchange. J Biol Chem. 1990;265(34):20982–20987.
   Google Scholar
• Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42(6):801–813.
   Google Scholar
• Sugahara M, Pak WLW, Tanaka T, et al. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology. 2021;26(6):491–500.
   Google Scholar
• Susztak K, Raff AC, Schiffer M, et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225–233.
   Google Scholar
• Reddy MA, Adler SG, Kim YS, et al. Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol. 2002;283(5):F985–94.
   Google Scholar
• Gallagher EJ, LeRoith D, Stasinopoulos M, et al. Polyol accumulation in muscle and liver in a mouse model of type 2 diabetes. J Diabetes Complications. 2016;30(6):999–1007.
   Google Scholar
• Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–146.
   Google Scholar
• Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol. 2011 Jul;1(3):1175–1232.
   Google Scholar
• Raj DS, Choudhury D, Welbourne TC, et al. Advanced glycation end products: a nephrologist’s perspective. Am J Kidney Dis. 2000;35(3):365–380.
   Google Scholar
• Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004 Dec;25(6):971–1010.
   Google Scholar
• Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia. 2001 Jun;44(6):659–673.
   Google Scholar
• Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998 Jun;47(6):859–866.
   Google Scholar
• Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007 Jan;87(1):245–313.
   Google Scholar
• Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol. 2003;14(8 Suppl 3):S227–32.
   Google Scholar
• Williams B, Gallacher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes. 1997;46(9):1497–1503.
   Google Scholar
• Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997;100(1):115–126.
   Google Scholar
• Balakumar P, Arora MK, Reddy J, et al. Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol. 2009;54(2):129–138.
   Google Scholar
• Baricos WH, Cortez SL, Deboisblanc M, et al. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol. 1999;10(4):790–795.
   Google Scholar
• Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest. 2004 Dec;34(12):785–796.
   Google Scholar
• Perez-Morales RE, Del Pino MD, Valdivielso JM, et al. Inflammation in diabetic kidney disease. Nephron. 2019;143(1):12–16.
   Google Scholar
• Jha JC, Banal C, Chow BS, et al. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal. 2016;25(12):657–684.
   Google Scholar
• Hesp AC, Schaub JA, Prasad PV, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 2020;98(3):579–589.
   Google Scholar
• DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021 May;17(5):319–334.
   Google Scholar
• Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023–1039.
   Google Scholar
• Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006 Jan;17(1):17–25.
   Google Scholar
• Koch EAT, Nakhoul R, Nakhoul F, et al. Autophagy in diabetic nephropathy: a review. Int Urol Nephrol. 2020;52(9):1705–1712.
   Google Scholar
• Kume S, Koya D. Autophagy: a novel therapeutic target for diabetic nephropathy. Diabetes Metab J. 2015 Dec;39(6):451–460.
   Google Scholar
• Inoki K. Inoki K. mTOR signaling in autophagy regulation in the kidney. Semin Nephrol. 2014 Jan;34(1):2–8.
   Google Scholar
• Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132–141.
   Google Scholar
• Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128–139.
   Google Scholar
• Lambers Heerspink HJ, Kröpelin TF, Hoekman J, et al. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2015;26(8):2055.
   Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;41(2):255–323.
   Google Scholar
• Kidney disease: improving global outcomes diabetes work G. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1–S115.
   Google Scholar
• American Diabetes A. 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S111–S124.
   Google Scholar
• Evert AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014;37(Suppl 1):S120–43.
   Google Scholar
• Delahanty LM, Nathan DM, Lachin JM, et al. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the diabetes control and complications trial. Am J Clin Nutr. 2009;89(2):518–524.
   Google Scholar
• Group DS. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325(7367):746.
   Google Scholar
• Klahr S, Buerkert J, Purkerson ML. Role of dietary factors in the progression of chronic renal disease. Kidney Int. 1983 Nov;24(5):579–587.
   Google Scholar
• Devries MC, Sithamparapillai A, Brimble KS, et al. Changes in kidney function do not differ between healthy adults consuming higher- compared with lower- or normal-protein diets: a systematic review and meta-analysis. J Nutr. 2018;148(11):1760–1775.
   Google Scholar
• Yan B, Su X, Xu B, et al. Effect of diet protein restriction on progression of chronic kidney disease: a systematic review and meta-analysis. PLoS One. 2018;13(11):e0206134.
   Google Scholar
• American Diabetes A. 5. Lifestyle management: standards of medical care in diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S46–S60.
   Google Scholar
• Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385(12):1067–1077.
   Google Scholar
• Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary Approaches to Stop Hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2020;11(5):1150–1160.
   Google Scholar
• Hamdy O, Mottalib A, Morsi A, et al. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study. BMJ Open Diabetes Res Care. 2017;5(1):e000259.
   Google Scholar
• Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
   Google Scholar
• Franz MJ, Boucher JL, Rutten-Ramos S, et al. Lifestyle weight-loss intervention outcomes in overweight and obese adults with Type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115(9):1447–1463.
   Google Scholar
• Vanhees L, Geladas N, Hansen D, et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol. 2012;19(5):1005–1033.
   Google Scholar
• Church TS, Cheng YJ, Earnest CP, et al. Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care. 2004;27(1):83–88.
   Google Scholar
• Kruger J, Galuska DA, Serdula MK, et al. Attempting to lose weight: specific practices among U.S. adults. Am J Prev Med. 2004;26(5):402–406.
   Google Scholar
• Maffiuletti NA, Agosti F, Marinone PG, et al. Changes in body composition, physical performance and cardiovascular risk factors after a 3-week integrated body weight reduction program and after 1-y follow-up in severely obese men and women. Eur J Clin Nutr. 2005;59(5):685–694.
   Google Scholar
• Ross R, Freeman JA, Janssen I. Exercise alone is an effective strategy for reducing obesity and related comorbidities. Exerc Sport Sci Rev. 2000 Oct;28(4):165–170.
   Google Scholar
• Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. Cmaj. 2006;174(6):801–809.
   Google Scholar
• Wei M, Gibbons LW, Kampert JB, et al. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med. 2000;132(8):605–611.
   Google Scholar
• Peti-Peterdi J, Kang JJ, Toma I. Activation of the renal renin-angiotensin system in diabetes–new concepts. Nephrol Dial Transplant. 2008 Oct;23(10):3047–3049.
   Google Scholar
• Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol. 2007 Mar;27(2):144–152.
   Google Scholar
• Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006 Jul;86(3):747–803.
   Google Scholar
• Patel BM, Mehta AA. Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. Eur J Pharmacol. 2012;697(1–3):1–12.
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878.
   Google Scholar
• Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–1578.
   Google Scholar
• Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63(4):1499–1507.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
   Google Scholar
• Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
   Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765–1772.
   Google Scholar
• Control G, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–2298.
   Google Scholar
• Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017;6: CD010137
   Google Scholar
• Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–2298.
   Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
   Google Scholar
• Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in Type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–426.
   Google Scholar
• Matthews DR, Paldanius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529.
   Google Scholar
• Kato S, Maruyama S, Makino H, et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clin Exp Nephrol. 2015;19(6):1098–1106.
   Google Scholar
• Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2641–2650.
   Google Scholar
• Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94‐8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385–1403.
   Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894.
   Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229.
   Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and Type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263.
   Google Scholar
• Wright EM. Glucose transport families SLC5 and SLC50. Mol Aspects Med. 2013 Apr-Jun;34(2–3):183–196.
   Google Scholar
• Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010 Feb;27(2):136–142.
   Google Scholar
• Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. 2021;33(4):732–739.
   Google Scholar
• Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018 Oct;61(10):2087–2097.
   Google Scholar
• Mackenzie B, Loo DD, Panayotova-Heiermann M, et al. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2. J Biol Chem. 1996;271(51):32678–32683.
   Google Scholar
• Coady MJ, Wallendorff B, Lapointe JY. Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na(+)-glucose cotransporter. Am J Physiol Renal Physiol. 2017;313(2):F467–F474.
   Google Scholar
• Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1):397–404.
   Google Scholar
• Cramer SC, Pardridge WM, Hirayama BA, et al. Colocalization of GLUT2 glucose transporter, sodium/glucose cotransporter, and gamma-glutamyl transpeptidase in rat kidney with double-peroxidase immunocytochemistry. Diabetes. 1992;41(6):766–770.
   Google Scholar
• Ehrenkranz JR, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–38.
   Google Scholar
• Chasis H, Jolliffe N, Smith HW. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest. 1933 Nov;12(6):1083–1090.
   Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51(5):1145–1149.
   Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90.
   Google Scholar
• Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl. 2011 Mar;120:S14–9.
   Google Scholar
• DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36(10):3169–3176.
   Google Scholar
• Pharmaceuticals J. Invokana (canagliflozin) prescribing information. NJ: Janssen Pharmaceuticals Titusville; 2020.
   Google Scholar
• AstraZeneca Pharmaceuticals L. FARXIGA™(dapa gliflozin) prescribing information. 2015.
   Google Scholar
• Ingelheim B. Jardiance (empagliflozin) prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals; 2020.
   Google Scholar
• Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–75 e9.
   Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597.
   Google Scholar
• Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–862.
   Google Scholar
• Lytvyn Y, Skrtic M, Yang GK, et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308(2):F77–83.
   Google Scholar
• Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442.
   Google Scholar
• Turkstra E, Braam B, Koomans HA. Nitric oxide release as an essential mitigating step in tubuloglomerular feedback: observations during intrarenal nitric oxide clamp. J Am Soc Nephrol. 1998 Sep;9(9):1596–1603.
   Google Scholar
• Thorup C, Persson AE. Inhibition of locally produced nitric oxide resets tubuloglomerular feedback mechanism. Am J Physiol. 1994 Oct;267(4 Pt 2):F606–11.
   Google Scholar
• Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol. 2003;65:501–529.
   Google Scholar
• Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307(3):F317–25.
   Google Scholar
• Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777.
   Google Scholar
• Yaribeygi H, Butler AE, Atkin SL, et al. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J Cell Physiol. 2018;234(1):223–230.
   Google Scholar
• Crippa G. Microalbuminuria in essential hypertension. J Hum Hypertens. 2002 Mar;16 Suppl 1:S74–7.
   Google Scholar
• Wells R, Rahman M. SPRINT and the kidney: what have we learned? Curr Hypertens Rep. 2018;20(11):95.
   Google Scholar
• Stack AG, Dronamraju N, Parkinson J, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with Type 2 diabetes: a randomized trial. Am J Kidney Dis. 2021;77(4):481–489.
   Google Scholar
• Akbari A, Rafiee M, Sathyapalan T, et al. Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis. J Diabetes Res. 2022;2022:7520632.
   Google Scholar
• Fioretto P, Stefansson BV, Johnsson E, et al. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016;59(9):2036–2039.
   Google Scholar
• Bae JH, Park EG, Kim S, et al. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):13009.
   Google Scholar
• Boulton DW, Kasichayanula S, Keung CF, et al. Simultaneous oral therapeutic and intravenous (1)(4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013;75(3):763–768.
   Google Scholar
• Kasichayanula S, Liu X, Zhang W, et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab. 2011;13(8):770–773.
   Google Scholar
• Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53(1):17–27.
   Google Scholar
• Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76(3):432–444.
   Google Scholar
• Kasichayanula S, Liu X, Zhang W, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011;33(11):1798–1808.
   Google Scholar
• Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1287–1302.
   Google Scholar
• Devineni D, Murphy J, Wang SS, et al. Absolute oral bioavailability and pharmacokinetics of canagliflozin: a microdose study in healthy participants. Clin Pharmacol Drug Dev. 2015;4(4):295–304.
   Google Scholar
• Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669–672.
   Google Scholar
• Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2015;9:5793–5803.
   Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–384.
   Google Scholar
• Li Y, Nucci G, Yamamoto Y, et al. Pharmacokinetics and pharmacodynamics of ertugliflozin in healthy Japanese and western subjects. Clin Pharmacol Drug Dev. 2021;10(7):765–776.
   Google Scholar
• Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39(9):1609–1619.
   Google Scholar
• Yang J. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2018 Aug;11(8):747–753.
   Google Scholar
• Dash RP, Babu RJ, Srinivas NR. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica. 2017 Nov;47(11):1015–1026.
   Google Scholar
• (FDA) FaDA. Highlights of prescribing information: steglatro (ertugliflozin). Food and Drug Administration; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf
   Google Scholar
• Sahasrabudhe V, Terra SG, Hickman A, et al. Pharmacokinetics of single-dose ertugliflozin in patients with hepatic impairment. Clin Ther. 2018;40(10):1701–1710.
   Google Scholar
• Sahasrabudhe V, Terra SG, Hickman A, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with Type 2 diabetes mellitus. J Clin Pharmacol. 2017;57(11):1432–1443.
   Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2018;380(4):347–357.
   Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in Type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435.
   Google Scholar
• Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction. Circulation. 2019;140(18):1463–1476.
   Google Scholar
• Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960.
   Google Scholar
• Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568–574.
   Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
   Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
   Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461.
   Google Scholar
• Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704.
   Google Scholar
• Jardine MJ, Zhou Z, Mahaffey KW, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol. 2020;31(5):1128–1139.
   Google Scholar
• Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–3370.
   Google Scholar
• FDA. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR); 2016 [cited 2020 Nov 6]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin
   Google Scholar
• Perlman A, Heyman SN, Matok I, et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017;27(12):1108–1113.
   Google Scholar
• Zhao M, Sun S, Huang Z, et al. Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. Clin J Am Soc Nephrol. 2020;16(1):70–78.
   Google Scholar
• Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:586–594.
   Google Scholar
• Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5):e001007.
   Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375–393.
   Google Scholar
• Alba M, Xie J, Fung A, et al. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(8):1375–1385.
   Google Scholar
• Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with Type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab. 2016;101(1):44–51.
   Google Scholar
• Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18(12):1199–1206.
   Google Scholar
• Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173(6):417–425.
   Google Scholar
• Arnott C, Huang Y, Neuen BL, et al. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab. 2020;22(10):1753–1766.
   Google Scholar
• Inzucchi SE, Iliev H, Pfarr E, et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(1):e4–e5.
   Google Scholar
• Zhuo M, Li J, Buckley LF, et al. Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease. Kidney360. 2022;3:455–464.
   Google Scholar
• The George Institute for Global Health. Global kidney patients trials network (GKPTN) Sydney; 2021 [cited 2021 Jul 7]. Available from: https://www.georgeinstitute.org/projects/global-kidney-patients-trials-network-gkptn
   Google Scholar